MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.33 2.31

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.29

Max

1.38

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.7M -24M
EPS	-0.354
Angestellte	49
EBITDA	-5.3M -28M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+103.82% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-624K 80M
Vorheriger Eröffnungskurs	-0.98
Vorheriger Schlusskurs	1.33

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Apr. 2026, 20:26 UTC

Akquisitionen, Fusionen, Übernahmen

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17. Apr. 2026, 18:15 UTC

Wichtige Nachrichtenereignisse

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17. Apr. 2026, 16:49 UTC

Wichtige Nachrichtenereignisse

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17. Apr. 2026, 16:49 UTC

Wichtige Nachrichtenereignisse

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17. Apr. 2026, 22:58 UTC

Ergebnisse

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17. Apr. 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17. Apr. 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Apr. 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17. Apr. 2026, 20:52 UTC

Ergebnisse

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17. Apr. 2026, 20:50 UTC

Market Talk

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

17. Apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Apr. 2026, 20:29 UTC

Ergebnisse

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17. Apr. 2026, 20:11 UTC

Akquisitionen, Fusionen, Übernahmen

UCB to Buy Neurona Therapeutics for Up to $1.15B

17. Apr. 2026, 19:34 UTC

Market Talk

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

17. Apr. 2026, 19:34 UTC

Market Talk

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17. Apr. 2026, 19:31 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17. Apr. 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

17. Apr. 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17. Apr. 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17. Apr. 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17. Apr. 2026, 18:57 UTC

Wichtige Nachrichtenereignisse

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17. Apr. 2026, 18:53 UTC

Akquisitionen, Fusionen, Übernahmen

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17. Apr. 2026, 18:53 UTC

Akquisitionen, Fusionen, Übernahmen

UCB 2026 Rev Guidance Unchanged

17. Apr. 2026, 18:52 UTC

Akquisitionen, Fusionen, Übernahmen

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17. Apr. 2026, 18:52 UTC

Akquisitionen, Fusionen, Übernahmen

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17. Apr. 2026, 18:14 UTC

Market Talk

Wichtige Nachrichtenereignisse

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17. Apr. 2026, 18:00 UTC

Wichtige Nachrichtenereignisse

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17. Apr. 2026, 18:00 UTC

Wichtige Nachrichtenereignisse

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17. Apr. 2026, 17:31 UTC

Market Talk

Wichtige Nachrichtenereignisse

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17. Apr. 2026, 17:26 UTC

Market Talk

Ergebnisse

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

103.82% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 103.82%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.